{"commentary":{"count":119,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":86,"podcast":16,"youtube":14,"x_video":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04446117\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CONTACT-02","nct_id":"NCT04446117","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=contact-02-nct04446117. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CONTACT-02","arms":[{"description":"Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w","label":"Experimental Arm","type":"EXPERIMENTAL"},{"description":"Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization","label":"Control Arm","type":"ACTIVE_COMPARATOR"}],"collaborators":["Roche-Genentech","Takeda"],"completion_date":{"date":"2026-10-16","type":"ESTIMATED"},"conditions":["Metastatic Prostate Cancer","Prostate Adenocarcinoma"],"enrollment":{"count":575,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Cabozantinib","type":"DRUG"},{"name":"Atezolizumab","type":"DRUG"},{"name":"Abiraterone Acetate","type":"DRUG"},{"name":"Enzalutamide","type":"DRUG"},{"name":"Prednisone","type":"DRUG"}],"last_update":"2025-12-18","lead_sponsor":"Exelixis","official_title":"A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-04-19","type":"ACTUAL"},"primary_outcomes":[{"measure":"Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)","timeFrame":"Up to a maximum of approximately 30 months (Median duration of follow-up was 14.31 months)"},{"measure":"Duration of Overall Survival (OS)","timeFrame":"Up to a maximum of approximately 45 months (Median duration of follow-up was 24.05 months)"}],"references":[{"citation":"Agarwal N, Azad AA, Carles J, Matsubara N, Oudard S, Saad F, Merseburger AS, Soares A, McGregor BA, Zurawski B, Tsiatas M, North S, Bondarenko I, Alfie M, Bournakis E, Antonuzzo L, Evilevitch L, Simmons A, Wang F, Ferraldeschi R, Nandoskar P, Pal SK. Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. Lancet Oncol. 2025 Jul;26(7):860-876. doi: 10.1016/S1470-2045(25)00209-8. Epub 2025 Jun 13.","pmid":"40523369","type":"DERIVED"},{"citation":"Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Mar;18(10):1185-1198. doi: 10.2217/fon-2021-1096. Epub 2022 Jan 17.","pmid":"35034502","type":"DERIVED"}],"start_date":{"date":"2020-10-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","url":"https://clinicaltrials.gov/study/NCT04446117"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/contact-02-nct04446117"}